NASDAQ:NOVN - Novan Stock Price, Price Target & More

$2.90 -0.14 (-4.61 %)
(As of 04/27/2018 02:57 AM ET)
Previous Close$2.90
Today's Range$2.84 - $3.0552
52-Week Range$2.65 - $7.33
Volume51,098 shs
Average Volume78,374 shs
Market Capitalization$79.68 million
P/E Ratio-1.25
Dividend YieldN/A
Beta1.22

About Novan (NASDAQ:NOVN)

Novan logoNovan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.

Receive NOVN News and Ratings via Email

Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NOVN
CUSIPN/A
Phone919-485-8080

Debt

Debt-to-Equity Ratio-0.01%
Current Ratio0.44%
Quick Ratio0.44%

Price-To-Earnings

Trailing P/E Ratio-1.25
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.14 million
Price / Sales35.29
Cash FlowN/A
Price / CashN/A
Book Value($0.09) per share
Price / Book-32.22

Profitability

EPS (Most Recent Fiscal Year)($2.32)
Net Income$-37,120,000.00
Net Margins-1,734.91%
Return on Equity-418.92%
Return on Assets-109.00%

Miscellaneous

Employees59
Outstanding Shares26,040,000

Novan (NASDAQ:NOVN) Frequently Asked Questions

What is Novan's stock symbol?

Novan trades on the NASDAQ under the ticker symbol "NOVN."

How were Novan's earnings last quarter?

Novan (NASDAQ:NOVN) posted its earnings results on Friday, May, 12th. The company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.24. The firm earned $0.10 million during the quarter, compared to analyst estimates of $10.80 million. Novan had a negative return on equity of 418.92% and a negative net margin of 1,734.91%. View Novan's Earnings History.

When is Novan's next earnings date?

Novan is scheduled to release their next quarterly earnings announcement on Friday, May, 11th 2018. View Earnings Estimates for Novan.

What price target have analysts set for NOVN?

2 analysts have issued 12-month price targets for Novan's stock. Their forecasts range from $6.00 to $6.00. On average, they expect Novan's stock price to reach $6.00 in the next twelve months. View Analyst Ratings for Novan.

Who are some of Novan's key competitors?

Who are Novan's key executives?

Novan's management team includes the folowing people:
  • Mr. Robert Alexander Ingram, Exec. Chairman (Age 76)
  • Mr. G. Kelly Martin, CEO & Director (Age 59)
  • Dr. Nathan Stasko Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 38)
  • Mr. Jeff N. Hunter, CFO, Chief Bus. Officer, Exec. VP & Company Sec. (Age 61)
  • Mr. Andrew Novak, VP & Chief Accounting Officer

When did Novan IPO?

(NOVN) raised $46 million in an initial public offering on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Has Novan been receiving favorable news coverage?

Media headlines about NOVN stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Novan earned a news sentiment score of 0.15 on Accern's scale. They also gave media stories about the company an impact score of 44.11 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Novan?

Shares of NOVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novan's stock price today?

One share of NOVN stock can currently be purchased for approximately $2.90.

How big of a company is Novan?

Novan has a market capitalization of $79.68 million and generates $2.14 million in revenue each year. The company earns $-37,120,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Novan employs 59 workers across the globe.

How can I contact Novan?

Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at 919-485-8080 or via email at [email protected]


MarketBeat Community Rating for Novan (NOVN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  105 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  230
MarketBeat's community ratings are surveys of what our community members think about Novan and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novan (NASDAQ:NOVN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Novan in the last 12 months. Their average twelve-month price target is $6.00, suggesting that the stock has a possible upside of 106.90%. The high price target for NOVN is $6.00 and the low price target for NOVN is $6.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.00$8.50$8.50$8.50
Price Target Upside: 106.90% upside57.41% upside57.41% upside57.41% upside

Novan (NASDAQ:NOVN) Consensus Price Target History

Price Target History for Novan (NASDAQ:NOVN)

Novan (NASDAQ:NOVN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/25/2017WedbushReiterated RatingNeutral$6.00HighView Rating Details
8/3/2017Piper JaffrayReiterated RatingBuyLowView Rating Details
10/17/2016Credit Suisse GroupInitiated CoverageOutperform$27.00 -> $18.97N/AView Rating Details
10/17/2016JMP SecuritiesInitiated CoverageOutperform$31.00N/AView Rating Details
(Data available from 4/27/2016 forward)

Earnings

Novan (NASDAQ:NOVN) Earnings History and Estimates Chart

Earnings by Quarter for Novan (NASDAQ:NOVN)

Novan (NASDAQ:NOVN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.26)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.21)($0.21)($0.21)
Q2 20181($0.27)($0.27)($0.27)
Q3 20181($0.35)($0.35)($0.35)
Q4 20181($0.43)($0.43)($0.43)

Novan (NASDAQ NOVN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2018        
8/11/2017Q2 2017($0.71)($0.62)$0.60 million$0.67 millionViewN/AView Earnings Details
5/12/2017Q1 2017($0.49)($0.73)$10.80 million$0.10 millionViewN/AView Earnings Details
3/20/2017Q4 16($1.1370)($0.82)ViewN/AView Earnings Details
11/14/2016Q3 16($1.40)($5.76)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Novan (NASDAQ:NOVN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Novan (NASDAQ NOVN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.72%
Institutional Ownership Percentage: 3.29%
Insider Trading History for Novan (NASDAQ:NOVN)
Insider Trading History for Novan (NASDAQ:NOVN)

Novan (NASDAQ NOVN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/29/2017Robert Alexander IngramDirectorBuy12,000$4.57$54,840.0061,312View SEC Filing  
8/23/2017John W PalmourDirectorBuy12,000$3.99$47,880.00253,568View SEC Filing  
9/26/2016Life Sciences Holdings L MalinMajor ShareholderBuy800,000$11.00$8,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Novan (NASDAQ NOVN) News Headlines

Source:
DateHeadline
Novans (NOVN) Buy Rating Reiterated at Piper JaffrayNovan's (NOVN) Buy Rating Reiterated at Piper Jaffray
www.americanbankingnews.com - April 13 at 6:01 PM
Same as the old boss — Novan makes interim CEO permanentSame as the old boss — Novan makes interim CEO permanent
finance.yahoo.com - April 13 at 10:09 AM
Novan (NOVN) Lowered to Sell at Zacks Investment ResearchNovan (NOVN) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 12 at 9:35 PM
Novan CEO drops interim labelNovan CEO drops interim label
seekingalpha.com - April 12 at 10:38 AM
Novan Inc (NASDAQ:NOVN): Poised For Long-Term Success?Novan Inc (NASDAQ:NOVN): Poised For Long-Term Success?
finance.yahoo.com - April 11 at 10:22 AM
Cramer: We got too negative on Friday—there's always a be...Cramer: We got too negative on Friday—there's always a be...
finance.yahoo.com - April 10 at 10:07 AM
Cramer: There's always a better time to sellCramer: There's always a better time to sell
finance.yahoo.com - April 10 at 10:07 AM
Novan (NOVN) Lifted to Sell at ValuEngineNovan (NOVN) Lifted to Sell at ValuEngine
www.americanbankingnews.com - April 3 at 11:11 AM
Novartis CEO on Alcon and SandozNovartis CEO on Alcon and Sandoz
finance.yahoo.com - March 27 at 10:09 AM
Novartis expands alliance with Science 37 to advance virtual clinical trials programNovartis expands alliance with Science 37 to advance virtual clinical trials program
finance.yahoo.com - March 7 at 9:47 AM
Novartis Xolair® recommended in new global chronic urticaria guidelineNovartis' Xolair® recommended in new global chronic urticaria guideline
finance.yahoo.com - March 6 at 9:33 AM
Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General MeetingNovartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
finance.yahoo.com - March 2 at 9:33 AM
Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosisNovartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis
finance.yahoo.com - March 1 at 9:22 AM
Treatment with Novartis Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflationTreatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
finance.yahoo.com - February 22 at 9:28 AM
Dr. Eugene Sun Appointed to Novan Board of DirectorsDr. Eugene Sun Appointed to Novan Board of Directors
finance.yahoo.com - February 21 at 9:52 AM
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasisNovartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
finance.yahoo.com - February 16 at 4:26 PM
Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasisNovartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis
finance.yahoo.com - February 16 at 4:26 PM
Novan Inc (NOVN) Expected to Post Earnings of -$0.55 Per ShareNovan Inc (NOVN) Expected to Post Earnings of -$0.55 Per Share
www.americanbankingnews.com - February 15 at 5:08 PM
Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasisNovartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis
finance.yahoo.com - February 8 at 9:03 AM
SAS founder Goodnights investment firm becomes Novans largest stockholderSAS founder Goodnight's investment firm becomes Novan's largest stockholder
finance.yahoo.com - January 30 at 4:37 PM
2 Novan execs out as company pushes to broaden focus2 Novan execs out as company pushes to broaden focus
finance.yahoo.com - January 25 at 4:34 PM
Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206
finance.yahoo.com - January 25 at 4:34 PM
Trading GE after earnings. Plus, the trade on Kroger & No...Trading GE after earnings. Plus, the trade on Kroger & No...
finance.yahoo.com - January 24 at 4:55 PM
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2017
finance.yahoo.com - January 24 at 4:55 PM
Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision lossNovartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss
finance.yahoo.com - January 24 at 4:55 PM
Novan (NOVN) Prices 10M Share Common Offering at $4.66/ShNovan (NOVN) Prices 10M Share Common Offering at $4.66/Sh
www.streetinsider.com - January 6 at 9:33 AM
Novan looks to raise $38M in public offeringNovan looks to raise $38M in public offering
finance.yahoo.com - January 5 at 5:04 PM
Novan (NOVN) Plans Common Stock OfferingNovan (NOVN) Plans Common Stock Offering
www.streetinsider.com - January 5 at 9:37 AM
Novan Announces Proposed Public Offering of Common Stock and WarrantsNovan Announces Proposed Public Offering of Common Stock and Warrants
finance.yahoo.com - January 4 at 5:19 PM
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline - January 2, 2018DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline - January 2, 2018
finance.yahoo.com - January 2 at 6:40 PM
Novan (NOVN) Stock Rating Upgraded by ValuEngineNovan (NOVN) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - January 1 at 3:10 PM
NOVAN 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit ...NOVAN 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Class Action Lawsuit ...
www.businesswire.com - December 31 at 9:20 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novan, Inc. of Class Action Lawsuit and Upcoming Deadline – NOVNSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Novan, Inc. of Class Action Lawsuit and Upcoming Deadline – NOVN
finance.yahoo.com - December 23 at 7:37 PM
Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its labelNovartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label
finance.yahoo.com - December 22 at 9:17 PM
Glancy Prongay & Murray LLP Announces the...Glancy Prongay & Murray LLP Announces the...
www.benzinga.com - December 21 at 9:31 AM
NOVN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novan, Inc. and a Lead Plaintiff Deadline of January 2, 2018NOVN SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novan, Inc. and a Lead Plaintiff Deadline of January 2, 2018
finance.yahoo.com - December 18 at 5:18 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline - January 2, 2018SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline - January 2, 2018
finance.yahoo.com - December 18 at 5:18 PM
NOVN INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Novan, Inc. InvestorsNOVN INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Novan, Inc. Investors
finance.yahoo.com - December 18 at 5:18 PM
Lawsuit for investors in NASDAQ:NOVN shares against Novan Inc announced by Shareholders FoundationLawsuit for investors in NASDAQ:NOVN shares against Novan Inc announced by Shareholders Foundation
finance.yahoo.com - December 18 at 9:50 AM
Scott+Scott, Attorneys at Law, LLP Reminds Investors of Securities Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline of January 2Scott+Scott, Attorneys at Law, LLP Reminds Investors of Securities Class Action Against Novan, Inc. (NOVN) and Lead Plaintiff Deadline of January 2
finance.yahoo.com - December 14 at 5:50 PM
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novan, Inc. of a Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 - NOVNEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novan, Inc. of a Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 - NOVN
finance.yahoo.com - December 14 at 9:39 AM
CORRECTING and REPLACING Robbins Arroyo LLP: Novan, Inc. (NOVN) Misled Shareholders According to a Recently Filed Class ActionCORRECTING and REPLACING Robbins Arroyo LLP: Novan, Inc. (NOVN) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - December 11 at 5:29 PM
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancerPrimary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
finance.yahoo.com - December 10 at 5:30 PM
Stocks tread lower, Bitcoin surges to record highStocks tread lower, Bitcoin surges to record high
finance.yahoo.com - December 8 at 9:32 AM
The Klein Law Firm Notifies Investors of a Class Action Commenced on Behalf of Novan, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018 (NOVN)The Klein Law Firm Notifies Investors of a Class Action Commenced on Behalf of Novan, Inc. Shareholders and a Lead Plaintiff Deadline of January 2, 2018 (NOVN)
finance.yahoo.com - December 7 at 5:43 PM
Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to...Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to...
finance.yahoo.com - December 6 at 5:18 PM
Stocks start in the green despite major tax bill concernsStocks start in the green despite major tax bill concerns
finance.yahoo.com - December 6 at 9:41 AM
IMPORTANT NOVAN, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Middle District of North Carolina against Novan, Inc.IMPORTANT NOVAN, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Middle District of North Carolina against Novan, Inc.
finance.yahoo.com - December 5 at 5:14 PM
Novan (NOVN) Reports First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414Novan (NOVN) Reports First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414
www.streetinsider.com - December 5 at 10:14 AM
NOVN EXPANDED CLASS: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novan, Inc. and a Lead Plaintiff Deadline of January 2, 2018NOVN EXPANDED CLASS: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novan, Inc. and a Lead Plaintiff Deadline of January 2, 2018
finance.yahoo.com - December 4 at 5:16 PM

SEC Filings

Novan (NASDAQ:NOVN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Novan (NASDAQ:NOVN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Novan (NASDAQ NOVN) Stock Chart for Friday, April, 27, 2018

Loading chart…

This page was last updated on 4/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.